{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:41:33Z","timestamp":1787020893287,"version":"build-2736575974"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T00:00:00Z","timestamp":1615161600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T00:00:00Z","timestamp":1615161600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008005","name":"Yonsei University College of Medicine","doi-asserted-by":"crossref","award":["6-2019-0184"],"award-info":[{"award-number":["6-2019-0184"]}],"id":[{"id":"10.13039\/501100008005","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["HI14C1324"],"award-info":[{"award-number":["HI14C1324"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To investigate whether serum chitinase-3-like 1 protein (YKL-40) is associated with disease activity in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>ELISA was performed in serum samples from AAV patients who were enrolled in our prospective observational cohort to estimate levels of YKL-40. Birmingham vasculitis activity score (BVAS) (version 3), five factor score (FFS), and short form-36 (SF-36), as well as clinical and laboratory data were collected. Kidney expression of YKL-40 was assessed by immunohistochemical staining using renal biopsy tissues from ANCA-associated glomerulonephritis patients (AAGN). Severe AAV and FFS were defined as BVAS \u2265\u200912 and FFS \u2265\u20092, and the correlations between laboratory variables, BVAS, FFS, and SF-36 score were assessed using linear regression analysis. The optimal cut-off of serum YKL-40 for severe AAV and high FFS was calculated using the receiver operator characteristic curve analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the included 60 patients, 32 (53.3%), 17 (28.3%), and 11 (18.3%) were classified as microscopic polyangiitis, granulomatosis with polyangiitis, and eosinophilic granulomatosis with polyangiitis. The median BVAS and FFS were 7.0 and 1.0, whereas the mean SF-36 physical and mental component scores were 50.5 and 58.3. Serum YKL-40 level was higher in patients with severe AAV and high FFS compared to those without (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.007 and\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001); multivariable linear regression analysis revealed that serum YKL-40 was independently associated with BVAS, FFS, and SF-36 scores. On kidney tissues obtained from AAGN patients, strong cytoplasmic staining of YKL-40 was found in cells present in inflammatory lesions. In addition, AAV patients had higher levels of serum YKL-40 compared to those with systemic lupus erythematosus, rheumatoid arthritis, osteoarthritis, and healthy control. The proportion of patients having severe AAV and high FFS was significantly higher in those with serum YKL-40 &gt;\u2009221.3\u2009ng\/mL and &gt;\u2009227.1\u2009ng\/mL than those without (relative risk 2.852 and 7.000). In 12 patients with serial YKL-40 testing, 11 patients (91.7%) exhibited a reduction in serum YKL-40 levels following a decrease in disease activity (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our findings suggest that serum YKL-40 may be a clinically useful biomarker to assess AAV disease activity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>Retrospectively registered.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13075-021-02467-1","type":"journal-article","created":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T01:02:44Z","timestamp":1615165364000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Serum chitinase-3-like 1 protein is a useful biomarker to assess disease activity in ANCA-associated vasculitis: an observational study"],"prefix":"10.1186","volume":"23","author":[{"given":"Sung Soo","family":"Ahn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taejun","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Beom","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Prendecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurjeet","family":"Bhangal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen P.","family":"McAdoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8038-3341","authenticated-orcid":false,"given":"Sang-Won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,8]]},"reference":[{"issue":"10","key":"2467_CR1","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.2215\/CJN.02500317","volume":"12","author":"JC Jennette","year":"2017","unstructured":"Jennette JC, Nachman PH. ANCA glomerulonephritis and vasculitis. Clin J Am Soc Nephrol. 2017;12(10):1680\u201391.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"2467_CR2","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.autrev.2012.08.008","volume":"12","author":"A Radice","year":"2013","unstructured":"Radice A, Bianchi L, Sinico RA. Anti-neutrophil cytoplasmic autoantibodies: methodological aspects and clinical significance in systemic vasculitis. Autoimmun Rev. 2013;12(4):487\u201395.","journal-title":"Autoimmun Rev"},{"issue":"10","key":"2467_CR3","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/nrrheum.2016.123","volume":"12","author":"D Cornec","year":"2016","unstructured":"Cornec D, Cornec-Le Gall E, Fervenza FC, Specks U. ANCA-associated vasculitis - clinical utility of using ANCA specificity to classify patients. Nat Rev Rheumatol. 2016;12(10):570\u20139.","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"2467_CR4","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s40674-016-0045-8","volume":"2","author":"S Gopaluni","year":"2016","unstructured":"Gopaluni S, Jayne D. Clinical trials in vasculitis. Curr Treat Options Rheumatol. 2016;2(2):161\u201377.","journal-title":"Curr Treat Options Rheumatol"},{"issue":"10","key":"2467_CR5","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s11926-013-0363-x","volume":"15","author":"L Lally","year":"2013","unstructured":"Lally L, Spiera RF. Biomarkers in ANCA-associated vasculitis. Curr Rheumatol Rep. 2013;15(10):363.","journal-title":"Curr Rheumatol Rep"},{"issue":"1","key":"2467_CR6","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1136\/ard.2008.097758","volume":"68","author":"PA Merkel","year":"2009","unstructured":"Merkel PA, Cuthbertson DD, Hellmich B, Hoffman GS, Jayne DR, Kallenberg CG, Krischer JP, Luqmani R, Mahr AD, Matteson EL, et al. Comparison of disease activity measures for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis. Ann Rheum Dis. 2009;68(1):103\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"2467_CR7","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1136\/ard.2008.101279","volume":"68","author":"C Mukhtyar","year":"2009","unstructured":"Mukhtyar C, Lee R, Brown D, Carruthers D, Dasgupta B, Dubey S, Flossmann O, Hall C, Hollywood J, Jayne D, et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis. 2009;68(12):1827\u201332.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2467_CR8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/MD.0b013e318205a4c6","volume":"90","author":"L Guillevin","year":"2011","unstructured":"Guillevin L, Pagnoux C, Seror R, Mahr A, Mouthon L, Le Toumelin P. The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore). 2011;90(1):19\u201327.","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"2467_CR9","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1002\/jbmr.5650070506","volume":"7","author":"JS Johansen","year":"1992","unstructured":"Johansen JS, Williamson MK, Rice JS, Price PA. Identification of proteins secreted by human osteoblastic cells in culture. J Bone Miner Res. 1992;7(5):501\u201312.","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2467_CR10","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s00011-006-0076-y","volume":"55","author":"CN Rathcke","year":"2006","unstructured":"Rathcke CN, Vestergaard H. YKL-40, a new inflammatory marker with relation to insulin resistance and with a role in endothelial dysfunction and atherosclerosis. Inflamm Res. 2006;55(6):221\u20137.","journal-title":"Inflamm Res"},{"key":"2467_CR11","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.ijcard.2019.06.058","volume":"293","author":"Y Sun","year":"2019","unstructured":"Sun Y, Kong X, Wu S, Ma L, Yan Y, Lv P, Jiang L. YKL-40 as a new biomarker of disease activity in Takayasu arteritis. Int J Cardiol. 2019;293:231\u20137.","journal-title":"Int J Cardiol"},{"issue":"12","key":"2467_CR12","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.1002\/1529-0131(199912)42:12<2624::AID-ANR17>3.0.CO;2-K","volume":"42","author":"JS Johansen","year":"1999","unstructured":"Johansen JS, Baslund B, Garbarsch C, Hansen M, Stoltenberg M, Lorenzen I, Price PA. YKL-40 in giant cells and macrophages from patients with giant cell arteritis. Arthritis Rheum. 1999;42(12):2624\u201330.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"2467_CR13","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1093\/rheumatology\/kez034","volume":"58","author":"Y van Sleen","year":"2019","unstructured":"van Sleen Y, Sandovici M, Abdulahad WH, Bijzet J, van der Geest KSM, Boots AMH, Brouwer E. Markers of angiogenesis and macrophage products for predicting disease course and monitoring vascular inflammation in giant cell arteritis. Rheumatology (Oxford). 2019;58(8):1383\u201392.","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"2467_CR14","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1080\/10408360802334743","volume":"45","author":"FD Coffman","year":"2008","unstructured":"Coffman FD. Chitinase 3-Like-1 (CHI3L1): a putative disease marker at the interface of proteomics and glycomics. Crit Rev Clin Lab Sci. 2008;45(6):531\u201362.","journal-title":"Crit Rev Clin Lab Sci"},{"issue":"2","key":"2467_CR15","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1158\/1055-9965.EPI-05-0011","volume":"15","author":"JS Johansen","year":"2006","unstructured":"Johansen JS, Jensen BV, Roslind A, Nielsen D, Price PA. Serum YKL-40, a new prognostic biomarker in cancer patients? Cancer Epidemiol Biomark Prev. 2006;15(2):194\u2013202.","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"6","key":"2467_CR16","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1080\/00365520310000537","volume":"38","author":"I Vind","year":"2003","unstructured":"Vind I, Johansen JS, Price PA, Munkholm P. Serum YKL-40, a potential new marker of disease activity in patients with inflammatory bowel disease. Scand J Gastroenterol. 2003;38(6):599\u2013605.","journal-title":"Scand J Gastroenterol"},{"issue":"5","key":"2467_CR17","doi-asserted-by":"publisher","first-page":"485","DOI":"10.5114\/ada.2018.77239","volume":"35","author":"J Salomon","year":"2018","unstructured":"Salomon J, Matusiak L, Nowicka-Suszko D, Szepietowski JC. Chitinase-3-like protein 1 (YKL-40) is a biomarker of severity of joint involvement in psoriatic arthritis. Postepy Dermatol Alergol. 2018;35(5):485\u20139.","journal-title":"Postepy Dermatol Alergol"},{"issue":"5","key":"2467_CR18","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1007\/s002960100115","volume":"20","author":"R Peltomaa","year":"2001","unstructured":"Peltomaa R, Paimela L, Harvey S, Helve T, Leirisalo-Repo M. Increased level of YKL-40 in sera from patients with early rheumatoid arthritis: a new marker for disease activity. Rheumatol Int. 2001;20(5):192\u20136.","journal-title":"Rheumatol Int"},{"issue":"7","key":"2467_CR19","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1093\/rheumatology\/38.7.618","volume":"38","author":"JS Johansen","year":"1999","unstructured":"Johansen JS, Stoltenberg M, Hansen M, Florescu A, H\u00f8rslev-Petersen K, Lorenzen I, Price PA. Serum YKL-40 concentrations in patients with rheumatoid arthritis: relation to disease activity. Rheumatology (Oxford). 1999;38(7):618\u201326.","journal-title":"Rheumatology (Oxford)"},{"key":"2467_CR20","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.jpba.2012.06.003","volume":"70","author":"PS Eastman","year":"2012","unstructured":"Eastman PS, Manning WC, Qureshi F, Haney D, Cavet G, Alexander C, Hesterberg LK. Characterization of a multiplex, 12-biomarker test for rheumatoid arthritis. J Pharm Biomed Anal. 2012;70:415\u201324.","journal-title":"J Pharm Biomed Anal"},{"issue":"4","key":"2467_CR21","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1159\/000442323","volume":"1","author":"H Xiao","year":"2016","unstructured":"Xiao H, Hu P, Falk RJ, Jennette JC. Overview of the pathogenesis of ANCA-associated vasculitis. Kidney Dis (Basel). 2016;1(4):205\u201315.","journal-title":"Kidney Dis (Basel)"},{"issue":"1","key":"2467_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.37715","volume":"65","author":"JC Jennette","year":"2013","unstructured":"Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, Flores-Suarez LF, Gross WL, Guillevin L, Hagen EC, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1\u201311.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"2467_CR23","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1136\/ard.2006.054593","volume":"66","author":"R Watts","year":"2007","unstructured":"Watts R, Lane S, Hanslik T, Hauser T, Hellmich B, Koldingsnes W, Mahr A, Segelmark M, Cohen-Tervaert JW, Scott D. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis. 2007;66(2):222\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"2467_CR24","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1007\/s11926-012-0291-1","volume":"14","author":"K Bhamra","year":"2012","unstructured":"Bhamra K, Luqmani R. Damage assessment in ANCA-associated vasculitis. Curr Rheumatol Rep. 2012;14(6):494\u2013500.","journal-title":"Curr Rheumatol Rep"},{"issue":"3","key":"2467_CR25","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1620\/tjem.203.189","volume":"203","author":"CW Han","year":"2004","unstructured":"Han CW, Lee EJ, Iwaya T, Kataoka H, Kohzuki M. Development of the Korean version of Short-Form 36-Item Health Survey: health related QOL of healthy elderly people and elderly patients in Korea. Tohoku J Exp Med. 2004;203(3):189\u201394.","journal-title":"Tohoku J Exp Med"},{"issue":"6 Suppl 43","key":"2467_CR26","first-page":"S-93","volume":"24","author":"C Mukhtyar","year":"2006","unstructured":"Mukhtyar C, Hellmich B, Jayne D, Flossmann O, Luqmani R. Remission in antineutrophil cytoplasmic antibody-associated systemic vasculitis. Clin Exp Rheumatol. 2006;24(6 Suppl 43):S-93\u20138.","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"2467_CR27","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s10735-006-9075-0","volume":"38","author":"M Ringsholt","year":"2007","unstructured":"Ringsholt M, Hogdall EV, Johansen JS, Price PA, Christensen LH. YKL-40 protein expression in normal adult human tissues--an immunohistochemical study. J Mol Histol. 2007;38(1):33\u201343.","journal-title":"J Mol Histol"},{"issue":"5","key":"2467_CR28","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1080\/030097401753180381","volume":"30","author":"JS Johansen","year":"2001","unstructured":"Johansen JS, Kirwan JR, Price PA, Sharif M. Serum YKL-40 concentrations in patients with early rheumatoid arthritis: relation to joint destruction. Scand J Rheumatol. 2001;30(5):297\u2013304.","journal-title":"Scand J Rheumatol"},{"issue":"7","key":"2467_CR29","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1136\/ard.59.7.544","volume":"59","author":"K Vos","year":"2000","unstructured":"Vos K, Steenbakkers P, Miltenburg AM, Bos E, van Den Heuvel MW, van Hogezand RA, de Vries RR, Breedveld FC, Boots AM. Raised human cartilage glycoprotein-39 plasma levels in patients with rheumatoid arthritis and other inflammatory conditions. Ann Rheum Dis. 2000;59(7):544\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"2467_CR30","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1093\/ckj\/sfw056","volume":"9","author":"JB Draibe","year":"2016","unstructured":"Draibe JB, Fulladosa X, Cruzado JM, Torras J, Salama AD. Current and novel biomarkers in anti-neutrophil cytoplasm-associated vasculitis. Clin Kidney J. 2016;9(4):547\u201351.","journal-title":"Clin Kidney J"},{"issue":"1","key":"2467_CR31","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1093\/rheumatology\/ker280","volume":"51","author":"G Tomasson","year":"2012","unstructured":"Tomasson G, Grayson PC, Mahr AD, Lavalley M, Merkel PA. Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis--a meta-analysis. Rheumatology (Oxford). 2012;51(1):100\u20139.","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"2467_CR32","first-page":"655","volume":"19","author":"T Matsumoto","year":"2001","unstructured":"Matsumoto T, Tsurumoto T. Serum YKL-40 levels in rheumatoid arthritis: correlations between clinical and laborarory parameters. Clin Exp Rheumatol. 2001;19(6):655\u201360.","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"2467_CR33","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1681\/ASN.2005101048","volume":"17","author":"JC Jennette","year":"2006","unstructured":"Jennette JC, Xiao H, Falk RJ. Pathogenesis of vascular inflammation by anti-neutrophil cytoplasmic antibodies. J Am Soc Nephrol. 2006;17(5):1235\u201342.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"2467_CR34","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1097\/MNH.0b013e3283456731","volume":"20","author":"JC Jennette","year":"2011","unstructured":"Jennette JC, Falk RJ, Gasim AH. Pathogenesis of antineutrophil cytoplasmic autoantibody vasculitis. Curr Opin Nephrol Hypertens. 2011;20(3):263\u201370.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2467_CR35","doi-asserted-by":"publisher","first-page":"256","DOI":"10.3389\/fimmu.2016.00256","volume":"7","author":"D Soderberg","year":"2016","unstructured":"Soderberg D, Segelmark M. Neutrophil extracellular traps in ANCA-associated vasculitis. Front Immunol. 2016;7:256.","journal-title":"Front Immunol"},{"issue":"12","key":"2467_CR36","doi-asserted-by":"publisher","first-page":"3988","DOI":"10.1002\/art.30615","volume":"63","author":"PA Monach","year":"2011","unstructured":"Monach PA, Tomasson G, Specks U, Stone JH, Cuthbertson D, Krischer J, Ding L, Fervenza FC, Fessler BJ, Hoffman GS, et al. Circulating markers of vascular injury and angiogenesis in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2011;63(12):3988\u201397.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"2467_CR37","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1136\/annrheumdis-2012-201981","volume":"72","author":"PA Monach","year":"2013","unstructured":"Monach PA, Warner RL, Tomasson G, Specks U, Stone JH, Ding L, Fervenza FC, Fessler BJ, Hoffman GS, Ikle D, et al. Serum proteins reflecting inflammation, injury and repair as biomarkers of disease activity in ANCA-associated vasculitis. Ann Rheum Dis. 2013;72(8):1342\u201350.","journal-title":"Ann Rheum Dis"},{"key":"2467_CR38","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/1475-2840-8-61","volume":"8","author":"CN Rathcke","year":"2009","unstructured":"Rathcke CN, Vestergaard H. YKL-40--an emerging biomarker in cardiovascular disease and diabetes. Cardiovasc Diabetol. 2009;8:61.","journal-title":"Cardiovasc Diabetol"},{"issue":"5","key":"2467_CR39","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1158\/1535-7163.MCT-10-0868","volume":"10","author":"M Faibish","year":"2011","unstructured":"Faibish M, Francescone R, Bentley B, Yan W, Shao R. A YKL-40-neutralizing antibody blocks tumor angiogenesis and progression: a potential therapeutic agent in cancers. Mol Cancer Ther. 2011;10(5):742\u201351.","journal-title":"Mol Cancer Ther"},{"key":"2467_CR40","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1146\/annurev-pathol-011811-132453","volume":"8","author":"JC Jennette","year":"2013","unstructured":"Jennette JC, Falk RJ, Hu P, Xiao H. Pathogenesis of antineutrophil cytoplasmic autoantibody-associated small-vessel vasculitis. Annu Rev Pathol. 2013;8:139\u201360.","journal-title":"Annu Rev Pathol"},{"issue":"1","key":"2467_CR41","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.semarthrit.2015.02.002","volume":"45","author":"A Berti","year":"2015","unstructured":"Berti A, Cavalli G, Campochiaro C, Guglielmi B, Baldissera E, Cappio S, Sabbadini MG, Doglioni C, Dagna L. Interleukin-6 in ANCA-associated vasculitis: rationale for successful treatment with tocilizumab. Semin Arthritis Rheum. 2015;45(1):48\u201354.","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"2467_CR42","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1681\/ASN.2009070763","volume":"21","author":"PY Gan","year":"2010","unstructured":"Gan PY, Steinmetz OM, Tan DS, O'Sullivan KM, Ooi JD, Iwakura Y, Kitching AR, Holdsworth SR. Th17 cells promote autoimmune anti-myeloperoxidase glomerulonephritis. J Am Soc Nephrol. 2010;21(6):925\u201331.","journal-title":"J Am Soc Nephrol"},{"key":"2467_CR43","doi-asserted-by":"publisher","first-page":"215140","DOI":"10.1155\/2014\/215140","volume":"2014","author":"T Vaananen","year":"2014","unstructured":"Vaananen T, Koskinen A, Paukkeri EL, Hamalainen M, Moilanen T, Moilanen E, Vuolteenaho K. YKL-40 as a novel factor associated with inflammation and catabolic mechanisms in osteoarthritic joints. Mediat Inflamm. 2014;2014:215140.","journal-title":"Mediat Inflamm"},{"issue":"2","key":"2467_CR44","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1681\/ASN.2012060579","volume":"24","author":"IM Schmidt","year":"2013","unstructured":"Schmidt IM, Hall IE, Kale S, Lee S, He CH, Lee Y, Chupp GL, Moeckel GW, Lee CG, Elias JA, et al. Chitinase-like protein Brp-39\/YKL-40 modulates the renal response to ischemic injury and predicts delayed allograft function. J Am Soc Nephrol. 2013;24(2):309\u201319.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"2467_CR45","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jaci.2015.11.020","volume":"138","author":"TS Hinks","year":"2016","unstructured":"Hinks TS, Brown T, Lau LC, Rupani H, Barber C, Elliott S, Ward JA, Ono J, Ohta S, Izuhara K, et al. Multidimensional endotyping in patients with severe asthma reveals inflammatory heterogeneity in matrix metalloproteinases and chitinase 3-like protein 1. J Allergy Clin Immunol. 2016;138(1):61\u201375.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"2467_CR46","doi-asserted-by":"publisher","first-page":"57","DOI":"10.11152\/mu-1247","volume":"1","author":"R Karalilova","year":"2018","unstructured":"Karalilova R, Kazakova M, Batalov A, Sarafian V. Correlation between protein YKL-40 and ultrasonographic findings in active knee osteoarthritis. Med Ultrason. 2018;1(1):57\u201363.","journal-title":"Med Ultrason"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-021-02467-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13075-021-02467-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-021-02467-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T01:04:17Z","timestamp":1615165457000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-021-02467-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,8]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2467"],"URL":"https:\/\/doi.org\/10.1186\/s13075-021-02467-1","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,8]]},"assertion":[{"value":"28 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board of Severance Hospital (4-2016-0901) and the patients\u2019 written informed consent was obtained at the time of blood sampling.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"77"}}